1. Home
  2. ATLN vs KYTX Comparison

ATLN vs KYTX Comparison

Compare ATLN & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATLN
  • KYTX
  • Stock Information
  • Founded
  • ATLN 2014
  • KYTX 2018
  • Country
  • ATLN United States
  • KYTX United States
  • Employees
  • ATLN N/A
  • KYTX N/A
  • Industry
  • ATLN
  • KYTX
  • Sector
  • ATLN
  • KYTX
  • Exchange
  • ATLN NYSE
  • KYTX NYSE
  • Market Cap
  • ATLN 137.6M
  • KYTX 125.2M
  • IPO Year
  • ATLN 2021
  • KYTX 2024
  • Fundamental
  • Price
  • ATLN $3.92
  • KYTX $1.86
  • Analyst Decision
  • ATLN
  • KYTX Buy
  • Analyst Count
  • ATLN 0
  • KYTX 5
  • Target Price
  • ATLN N/A
  • KYTX $18.80
  • AVG Volume (30 Days)
  • ATLN 54.0K
  • KYTX 298.8K
  • Earning Date
  • ATLN 01-01-0001
  • KYTX 05-13-2025
  • Dividend Yield
  • ATLN N/A
  • KYTX N/A
  • EPS Growth
  • ATLN N/A
  • KYTX N/A
  • EPS
  • ATLN N/A
  • KYTX N/A
  • Revenue
  • ATLN $442,609,814.00
  • KYTX N/A
  • Revenue This Year
  • ATLN N/A
  • KYTX N/A
  • Revenue Next Year
  • ATLN N/A
  • KYTX N/A
  • P/E Ratio
  • ATLN N/A
  • KYTX N/A
  • Revenue Growth
  • ATLN 10.27
  • KYTX N/A
  • 52 Week Low
  • ATLN $1.30
  • KYTX $1.79
  • 52 Week High
  • ATLN $8.98
  • KYTX $22.44
  • Technical
  • Relative Strength Index (RSI)
  • ATLN N/A
  • KYTX 39.01
  • Support Level
  • ATLN N/A
  • KYTX $1.81
  • Resistance Level
  • ATLN N/A
  • KYTX $2.27
  • Average True Range (ATR)
  • ATLN 0.00
  • KYTX 0.21
  • MACD
  • ATLN 0.00
  • KYTX 0.02
  • Stochastic Oscillator
  • ATLN 0.00
  • KYTX 16.33

About ATLN ATLANTIC INTERNATIONAL CORP

Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Share on Social Networks: